Skip to content

Effect of remimazolam or propofol sedation on the quality of recovery after colonoscopy

Effect of remimazolam or propofol sedation on the quality of recovery after colonoscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056092
Enrollment
Unknown
Registered
2022-01-31
Start date
2022-01-24
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy

Interventions

Remimazolam group:Fentanyl 1ug/kg was administered to patients by intravenous injection before the assigned trial sedatives. Give the initial dose of 5.0 mg of remimazolam. If sufficient sedation is n
Propofol Group:Fentanyl 1ug/kg was administered to patients by intravenous injection before the assigned trial sedatives. An initial dose of 1.5 mg/kg of propofol is given. If sufficient sedation is n

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Planned to undergo outpatient colonoscopy; 2. Age >=18 years; 3. American Society of Anesthesiologists (ASA) physical status I-III; 4. Patients voluntarily participate in the trial and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. About to receive endotracheal intubation or laryngeal mask; 2. Required complex endoscope procedures (such as endoscopic submucosal dissection, etc.); 3. Psychiatric disorders (schizophrenia, mania, etc.) and cognitive impairment; 4. History of drug/alcohol abuse within two years (Alcohol abuse: average daily consumption of more than 2 units of alcohol, 1 unit of alcohol = 360 mL5% beer or 45 mL 40% liquor or 150 mL 10-15% red wine); 5. Pregnant or breastfeeding women; 6. Known sensitivity or contraindication to benzodiazepines, opioids and propofol; 7. Unable to understand the recovery quality scale and difficult to complete the recovery quality survey.

Design outcomes

Primary

MeasureTime frame
The incidence of overall recovery (recovery in all subdomains) of the PostopQRS;

Secondary

MeasureTime frame
Recovery across all time points over 3 months for each PostopQRS domain and overall recovery;Patient satisfaction and endoscopist satisfaction with surgical conditions;Incidence of adverse events, including hypotension (SBP or DBP <80% of the baseline), bradycardia (HR<50bpm), hypoxia (SpO2<90%), injection site pain, dizziness, abnormal gait, nausea and vomiting and diarrhea;Induction time of sedation (from administration to meet the colonoscopy requirements), sedation duration (from administration to eye opening), time to eye-opening (from the last dose to eye opening), and time to discharge from the recovery room (from the end of colonoscopy to leave the recovery room);

Countries

China

Contacts

Public Contactunyi i

Affiliated Hospital of Xuzhou Medical University

9472540@qq.com+86 15162159886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026